3 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow PF-05190457: new trials by email Literature Review of PF-05190457 trials Research Report on PF-05190457
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II PF-05190457, Placebo - Alcoholism | Phase 2 | Terminated | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 42 | 2016-06-15 | 2022-03-16 |
| A Novel Compound for Alcoholism Treatment PF-05190457 - Alcoholism, Alcohol-Related Disorders | Phase 1 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 14 | 2014-01-03 | 2019-12-16 |
| A Study Of Three PF-05190457 Formulations In Healthy Volunteers PF-05190457 - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Pfizer | 16 | 2011-09-01 | 2012-02-01 |
| Single Dose Escalation Study of PF-05190457 in Healthy Volunteers PF-05190457, Placebo - Diabetes Mellitus, Type II | Phase 1 | Completed | Pfizer | 26 | 2010-12-01 | 2011-07-06 |
Alcohol Drinking (2) · Alcoholism (2) · Diabetes Mellitus, Type 2 (2) · Alcohol-Related Disorders (1)
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2) · Pfizer (2)
United States (2) · Belgium (1) · Singapore (1)
Lorenzo Leggio, M.D. (1) · Lorenzo Leggio, M.D., PhD (1)
PMID 33155163, PMID 27621150, PMID 31557492, PMID 39704175, PMID 41474196